Area of Science:

• Cardiology
• Biomedical Engineering

Background:

• Heart failure (HF) poses a significant global health challenge, impacting quality of life and incurring substantial economic costs.
• Atrial fibrillation (AF) in HF patients exacerbates risks, leading to increased hospitalizations and mortality.
• Existing treatments, while effective, necessitate ongoing research for improved prophylaxis and management strategies.

Purpose of the Study:

• To evaluate the potential of the Optimizer Smart® system for cardiac contractility modulation (CCM) in HF patients.
• To explore CCM as a treatment option for HF patients with AF who are not candidates for or have not benefited from cardiac resynchronization therapy (CRT).

Main Methods:

• The study focuses on the Optimizer Smart® system, a novel cardiac contractility modulation device.
• The research investigates its application in a specific patient cohort: those with heart failure and atrial fibrillation.
• Patient selection criteria include ineligibility or poor response to conventional cardiac resynchronization therapy (CRT).

Main Results:

• The Optimizer Smart® system presents a promising therapeutic avenue.
• It offers a potential treatment for heart failure patients experiencing atrial fibrillation.
• This approach is particularly relevant for individuals who do not benefit from or cannot undergo cardiac resynchronization therapy (CRT).

Conclusions:

• The Optimizer Smart® system represents a novel and perspective treatment for heart failure.
• It addresses a critical unmet need in patients with co-existing atrial fibrillation and CRT limitations.
• Further research and clinical application of CCM are warranted to improve outcomes in this challenging patient population.